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Abstract
Background This study assessed the effectiveness of
computerized measurement and feedback of health-related
quality of life (HRQoL) in daily clinical practice in patients
with chronic liver disease.
Methods One hundred and sixty-two patients (61% men;
mean age 47.5 years) regularly completed computerized
HRQoL questionnaires before each consultation for the
duration of 1 year. Six physicians were randomly assigned
to the experimental group and received an instant online
graphical output of data. Five other physicians were ran-
domly assigned to the control group and conducted their
consultations as usual. Differences between groups on
generic- and disease-speciﬁc HRQoL, patient management,
and patient satisfaction with the consultation were asses-
sed, as were physicians’ experiences with HRQoL data and
effects on their consultations.
Results No direct effect of the experimental condition on
patients’ HRQoL was found. However, an interaction
effect of the experimental condition and age was found:
older patients in the experimental group had signiﬁcantly
better disease-speciﬁc HRQoL (F = 4.16; P = 0.04) and
generic mental HRQoL (F = 4.62; P = 0.03) than patients
in the control group. Also, male patients in the experi-
mental group had better generic mental HRQoL than
patients in the control group (F = 6.10; P = 0.02). Physi-
cians in the experimental group altered their treatment policy
signiﬁcantly more often than did physicians in the control
group (z =- 3.73, P = 0.00), and their experiences with the
availability of HRQoL information were generally positive.
The scores on patient satisfaction with the consultation did
not differ signiﬁcantly between the experimental and control
groups (z =- 1.20, P = 0.23).
Conclusions Computerized measurement and feedback of
HRQoL in a daily clinical practice of an outpatient
department of hepatology did not improve HRQoL for the
entire group of chronic liver patients but, rather, improved
disease-speciﬁc HRQoL of older patients with chronic liver
disease and mental HRQoL of older patients and male
patients with chronic liver disease. It also had an effect on
patient management.
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Introduction
Health-related quality of life (HRQoL), or psychological,
social,andphysicalfunctioning[1],hasbecomeanimportant
outcome measure in medical care. Standardized assessment
of HRQoL preceding each consultation may potentially
provide physicians with valuable information. Several stud-
ies have shown that physicians vary in their ability to elicit
psychosocialinformation or thattheyunderestimate patients’
HRQoL [2–5]. Furthermore, various studies have shown that
when communication with the physician encompasses both
physical and psychosocial issues, patients have better treat-
ment compliance, are more satisﬁed with the consultation,
and report less symptoms [6–8].
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value of HRQoL measurement in clinical practice. Some
have shown positive results with regard to acceptance by
patients and physicians or a signiﬁcant increase in the
identiﬁcation and/or discussion of HRQoL issues [9–14].
Less consistent and favorable results have been obtained
with regard to the effectiveness of standardized HRQoL
measurement in actually improving HRQoL or psychoso-
cial outcomes. Even though decreased depression [15],
improved overall and emotional functioning [10],
improved mental health [16], and a decrease in disease-
speciﬁc debilitating symptoms of patients undergoing
chemotherapy [13] have been associated with HRQoL
measurement in clinical practice, several other studies
found no signiﬁcant improvement in HRQoL or psycho-
social outcomes [9, 17–20]. A possible explanation might
be that the majority of existing studies assessing the
effectiveness of HRQoL measurement in clinical practice
with regard to patients’ psychosocial functioning or
HRQoL have included oncological patients or patients
from general practice. Oncological patients can be con-
sidered a special group due to the life-threatening nature of
the disease. Patients from general practice, on the other
hand, may be too diverse and often present with generally
minor complaints, which may hamper the discovery of
beneﬁcial effects. Both groups impede generalization of
results to other chronic patient populations.
Two important studies [9, 10] used designs in which
physicians were part of both the control and the experi-
mental group, either by using a crossover design
(physicians were ﬁrst assigned to one group, then crossed
over to the other group halfway through the study) [9]o rb y
assigning patients rather than physicians to the different
groups [10]. This may possibly have caused bias. Two
systematic reviews have stressed the need for further
research evaluating the effectiveness of repeated mea-
surements of HRQoL in clinical practice [18, 20] and the
need for further research to help health care professionals
identify patients who would beneﬁt most from such inter-
ventions [20].
The study reported here differs from previous studies by
including a patient population with chronic liver disease
(CLD) in order to study the effects of HRQoL use in
clinical practice in a population that is more representative
of other patients with a chronic disease. CLD is one of the
most prevalent diseases in the world. The most common
causes of CLD, hepatitis B virus (HBV) and hepatitis C
virus (HCV), have been estimated to affect 360 million and
200 million people worldwide, respectively (http://www.
epidemic.org, 4-12-2006). In addition, alcohol is another
main cause of end-stage liver disease worldwide and the
second most common reason for liver transplantation in the
United States [21]. CLD is a serious disease that is
associated with signiﬁcant physical and psychological
symptoms such as impaired cognition, hepatic coma, ﬂuid
in the abdomen, abdominal pain, joint pain, fatigue,
depression, and anxiety [22–28]. Not surprisingly, HRQoL
in patients with CLD has been shown to be impaired [29,
30]. CLD is an appropriate example of a typical chronic
disease, with patients experiencing substantial comorbidity
and possibly mortality, as is the case in other chronic
diseases such as kidney disease and chronic obstructive
pulmonary disease.
Our study also differs from previous studies by assessing
the beneﬁts of HRQoL measurement for patients with
different demographic characteristics (e.g., men and
women, young and old), which is essential for determining
which patients are most likely to beneﬁt from HRQoL
measurement in clinical practice, a point recently reiterated
in a systematic review on this topic [20]. In addition, in our
study, physicians rather than patients were assigned to the
control or the experimental group. This assigning of phy-
sicians to only one group prevents bias of physicians being
focused on discussing HRQoL when seeing patients in the
control group.
The aims of the study were twofold: the ﬁrst was to
assess the effectiveness of real-time computerized mea-
surement of HRQoL in various patients with CLD and
presentation of the results to physicians before the con-
sultation in terms of improvement in patient HRQoL,
patient management, and patient satisfaction with the
consultation by means of a randomized trial with repeated
measurements. The second aim was to assess hepatolo-
gists’ experiences with the availability of real-time HRQoL
patient data and to measure the possible effect(s) it had on
their consultations.
Patients and methods
Patient recruitment
This study was performed at the Department of Gastroen-
terology and Hepatology of the Erasmus Medical Centre,
Rotterdam, where HRQoL measurement on a regular basis
was implemented for the duration of 1 year. All patients
older than 17 years of age with CLD visiting the depart-
ment between September 2004 and January 2005 were
invited to participate. Written information about the study
was sent to the patients 3 days before their consultation at
the outpatient department. Patients interested in partici-
pating informed their physician, who consequently directed
them to the researcher for further explanation of the study
and to sign informed consent. For this effectiveness study,
we included all patients with two or more measurement
moments. All physicians working at the Department of
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with the ethical guidelines of the modiﬁed 1975 Declara-
tion of Helsinki and approved by the Medical Ethics
Committee of the Erasmus MC.
Study objectives
The primary aim of this study was to assess the effec-
tiveness of computerized measurement of HRQoL in
clinical practice. The primary outcome measures were
patients’ generic HRQoL (physical and mental component
score separately) and disease-speciﬁc HRQoL. Secondary
outcome measures were patient satisfaction with the con-
sultation and patient management. The secondary aim of
this study was to assess hepatologists’ experiences with the
availability of real-time HRQoL patient data.
Study design and intervention
Physicians
Physicians were randomly assigned to either the experi-
mental or control group by means of a restricted
randomization procedure called blocking. To ensure an
equal number of physicians in each group, it was decided
to include six in the experimental group and ﬁve in the
control group. We used a random sequence table to assign
physicians to one of the conditions. Due to the nature of the
intervention, it was impossible to blind physicians to group
assignment.
Physicians in the experimental group were able to obtain
an instant computerized graphical output of HRQoL patient
data, which also included data from previous measurement
moments so that changes in patients’ HRQoL could be
monitored (Fig. 1). Prior to the study, physicians received
instructions from a psychologist with expertise in the ﬁeld
of HRQoL measurement on how to interpret this output.
First, physicians were shown the questionnaires in order to
familiarize them with the content. Second, they were
informed that the red line in the graph was the average
score of patients with CLD on the Short Form-36 (SF-36)
measuring generic HRQoL and that scores under this line
were to be considered low. They were also told that the
average score of healthy people on this questionnaire was
50. The physicians were instructed to interpret the disease-
speciﬁc Liver Disease Symptom Index 2.0 (LDSI 2.0) at
item level, with scores ranging from 1 (not at all) to 5 (to a
large extent). The physicians were asked to use the HRQoL
data in all consultations for 1 year. No recommendations
for speciﬁc responses were given. Instead, they were
instructed to use their clinical experience to choose an
appropriate treatment. After seeing a participating patient,
physicians in both groups completed a checklist about the
content of the consultation. Physicians in the control group
conducted their consultations as usual.
Patients
Through the random assignment of physicians, patients
were indirectly allocated to either group. Patients were
initially blinded to the group assignment. All patients
participating in the study completed a computerized gen-
eric- and disease-speciﬁc HRQoL questionnaire and the
ﬁrst part of a pen-and-paper questionnaire on patient sat-
isfaction with the consultation before each consultation at
the outpatient Department of Hepatology for 1 year. They
also completed the second part of the satisfaction ques-
tionnaire after the consultation. More speciﬁc information
on the content of the questionnaires is provided in ‘‘Study
measures’’. To ascertain good questionnaire completion,
a researcher was always available to answer questions
about the computer and/or questionnaires at the patient’s
request.
Study measures
HRQoL
Disease-speciﬁc HRQoL: This was assessed by means of
the LDSI 2.0, which measures severity and hindrance of
nine symptoms: itch, joint pain, pain in the right upper
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Fig. 1 Example of the graphical output of patients’ health-related
quality of life as presented to physicians in the intervention group. A
score of 50 is the average score of a healthy norm population. The
dashed line represents the mean score for patients with chronic liver
disease
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123abdomen, decreased appetite, jaundice, fatigue, depressed
mood, worries about family situation, and fear of compli-
cations [24]. Because of time constraints, only items
measuring symptom severity were included in this study
(n = 9). The physicians were instructed to interpret the
questionnaire at item level, with scores ranging from 1 (not
at all) to 5 (to a large extent). For data analysis, a total
score, ranging from 9 to 45, was computed by summing
the scores of each item. The reliability of the LDSI 2.0 is
good (internal consistency a[0.79), as is the construct
validity [30].
Generic HRQoL: This was assessed by means of the
Short Form-12 version 1 (SF-12). The SF-12 produces a
Physical Component Summary (PCS) and Mental Com-
ponent Summary (MCS), representing physical and
emotional functioning, respectively. The mean score of
the PCS and MCS in the generalpopulation is50 [standard
deviation (SD) 10] with higher scores representing better
HRQoL.MeanscoresandSDofthePCSandMCSofCLD
patients was calculated from a large database (n = 1,175)
[29, 31] (PCS: mean 43.2, SD 10.7; MCS: mean 44.4,
SD 12.8). These means were used as a reference point (red
line) in the graphical representation for physicians so they
could easily identify patients scoring below average
within the CLD group. The SF-12 has been shown to
be reliable between test and retest (MCS r = 0.76, PCS
r = 0.89), and median relative validity estimates of
0.67–0.97 for the PCS and MCS, respectively, have been
found [32].
Patient satisfaction with the consultation
Patients’ satisfaction with the consultation was measured
with the QUOTE-Liver, a newly developed questionnaire
consisting of 20 items that assesses the discrepancy
between patients’ needs/expectations (importance: mea-
sured before the consultation) and the actual care that they
receive (performance: measured after the consultation).
The internal consistency of the overall QUOTE-Liver was
excellent (a = 0.90), as was the face validity: all patients
(n = 152) in the validation study and three psychologists
and a hepatologist agreed that the items of the QUOTE-
Liver adequately reﬂected the most important aspects of
care for CLD patients. Construct validity, as measured by
the correlation between a visual analog scale (VAS) mea-
suring overall satisfaction and the total score on the
QUOTE-Liver was good (r = 0.69; P\0.01). Content
validity was also good: none of the 152 patients in the
validation study suggested new items to be included
(Gutteling et al. 2006, unpublished). A reduced version
consisting of the nine items ranked by patients as most
important and the two liver-disease-speciﬁc items was used
in our study. Using a formula applied for all QUOTE-Liver
instruments (10-importance 9 performance), a total satis-
faction score can be computed ranging from 0 to 10, with 0
meaning not satisﬁed at all and 10 meaning completely
satisﬁed [33].
Patient management
The effect of the intervention on patient management was
measured by means of a checklist that physicians completed
after each consultation with a study participant, including the
question: ‘‘Have you changed your treatment in any way?’’
and a subquestion: ‘‘If so, whathaveyou done?’’ followed by
several options: ‘‘Prescription of antidepressants,’’ ‘‘Referral
to psychosocial care,’’ ‘‘Altering the frequency of consulta-
tions,’’ and ‘‘Other.’’
Physicians’ experiences
Experiences of physicians with the experimental condition
were assessed through the checklists that they completed
after each consultation with a study participant, asking the
question: ‘‘Did you ﬁnd the HRQoL information useful?
Why?’’ with the answering options: ‘‘Yes, it provided
new information,’’ ‘‘Yes, it saved time,’’ ‘‘Yes...,’’ ‘‘No, the
patient is doing well,’’ ‘‘No, I know this patient well
enough,’’ ‘‘No, the patient tells me a lot,’’ ‘‘No...’’. Also, a
semistructured interview was conducted 6 months into the
study and at the end of the study. The interview included
questions about the effort to request HRQoL information,
the usefulness of the information, whether the availability
of HRQoL information increased the duration of the con-
sultation, and whether participating patients addressed
HRQoL issues more often than patients who did not par-
ticipate. Physicians were also asked whether there were
certain subgroups of patients whose HRQoL information
they found particularly useful. Opinions of physicians in
the control group toward possible future availability of
HRQoL information during the consultation were assessed
by means of the same semistructured interview at 6 months
only.
Statistical analysis
Sample size
A nonclustered power analysis based on a medium effect
size (Cohen’s D = 0.50) with a 5% signiﬁcance level and
80% power indicated that at least 64 patients were needed
in each group to detect a statistically signiﬁcant difference.
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For patients who were included in both groups because they
had consultations with physicians from the control group as
well as physicians from the experimental group during the
year of the study, data from the condition in which they had
most often been was included (n = 33). For patients who
had been in both conditions equally (n = 19), all data were
excluded. The ﬁrst measurement moment of all patients (T1)
was considered a baseline measure, as no HRQoL data had
yet been presented to the physicians.
Data analysis
Differences on the variables gender, diagnosis, disease
severity, and age between participants and nonparticipants
were assessed by means of v
2 tests or t tests. The same was
done for assessing differences between patients in the
control group and the intervention group. Scores of par-
ticipating patients on measurement moments (T2-Ti) were
summarized into one overall score per variable in the
study. Univariate analyses of variance were performed in
SPSS 11.0. Fixed factors were age, gender, disease sever-
ity, presentation of HRQoL data to the clinicians
(feedback), and interactions between these variables. Dif-
ferences in diagnoses between patients in both groups were
controlled for by entering one propensity score of the
variable diagnosis as a covariate in the analyses. Propensity
scores were especially designed for situations in which
study participants could not be randomly assigned to
groups, and their characteristics were therefore not bal-
anced among the groups. A propensity score was deﬁned as
the conditional probability of assignment to a certain
treatment group given a set of observed pretreatment
characteristics and was usually estimated by means of a
logistic regression analysis [34]. Thereby, the background
characteristic(s), in this case diagnosis, was reduced to one
single score, the propensity score. We calculated the pro-
pensity score by entering the different diagnoses (HBV,
HCV, cholestatic liver disease, pretransplantation, post-
transplantation, autoimmune hepatitis, and other) as
dummy variables (M-1) in a logistic regression analysis.
The unstandardized logistic regression weights were then
multiplied by the relevant dummy variable and summed,
together with the constant. This score was used in the
univariate analysis to adjust for baseline confounding.
Univariate analyses of variance were performed for each
outcome variable (disease-speciﬁc HRQoL and generic
HRQoL MCS and PCS) separately. A forward technique was
used in which the main effects of the ﬁxed factors were
assessed in the ﬁrst block, and the interactions between
feedback of HRQoL data and each of the other ﬁxed factors
(age, gender, severity of the disease) were explored in the
second block. Differences between the two groups on patient
management variables and satisfaction with the consultation
were assessed by means of Mann–Whitney tests.
Hepatologists’ experiences with the availability of real-
time patient HRQoL data was assessed by means of
semistructured interviews and checklists. These data were
of a descriptive nature and are presented as such.
Results
Characteristics of patients and physicians in the study
Of the 587 patients that agreed to participate in the study,
181 completed the questionnaires more than once. Of
these, 19 were included in the experimental and control
conditions equally often and were therefore excluded from
the analyses. One hundred and sixty-two patients (control
group n = 80, experimental group n = 82) were included
(Fig. 2). Differences in age, gender, diagnosis, and disease
severity between patients in the study and nonrespondents
are presented in Table 1. Demographic characteristics of
the 162 patients are presented in Table 2. Patients in the
control and experimental groups were comparable, except
for the variables diagnosis and disease severity (Table 2).
In the analyses, these differences between conditions were
controlled for. All physicians working at the Department of
Hepatology (n = 11, ten men) agreed to participate. Their
mean age was 39 (range 27–55) years, and their average
working experience was 8.7 (range 0–27) years.
Descriptives
The number of times that patients in the control and
experimental groups completed the questionnaires varied
between two and 11 (Table 3). Mean scores of patients at
T1 and T2-Ti on the outcome variables generic HRQoL
and disease-speciﬁc HRQoL are presented in Table 4.
Effects of the experimental condition on patients’
HRQoL and satisfaction with the consultation
Disease-speciﬁc HRQoL
There was no main effect for the experimental condition on
disease-speciﬁc HRQoL. There was a statistically signiﬁ-
cant interaction effect for the variables age and feedback of
HRQoL data on the outcome variable disease-speciﬁc
HRQoL (Table 5): older patients ([48 years of age, as
determined by the median split) in the experimental
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2.0 (meanAdj = 18.1, 95% CI: 15.3–21.0) (F = 4.18;
P\0.05), indicating better disease-speciﬁc HRQoL, than
other patients, especially older patients in the control group
(meanAdj = 22.1, 95% CI: 19.9–24.3). This difference
between older patients in the experimental group and the
control group on disease-speciﬁc HRQoL is equivalent to a
Cohen’s D of 0.51, reﬂecting a medium difference [35].
Generic HRQoL
Mental Component Summary score No main effect for
the experimental condition on mental HRQoL was found.
However, a signiﬁcant interaction effect for the variables
age and feedback of HRQoL data was found. Older patients
in the experimental group had higher scores on the SF-12
MCS (meanAdj = 45.9, 95% CI: 41.6–50.3) (F = 4.62;
P\0.05), reﬂecting better HRQoL, than other patients,
especially older patients in the control group (meanAdj =
41.3, 95% CI: 37.8–44.7) (Table 6). Furthermore, a sig-
niﬁcant interaction effect was found for the variables
gender and feedback of HRQoL data, with male patients in
the experimental group showing higher scores on the SF-12
MCS (meanAdj = 46.7, 95% CI: 42.1–51.2) (F = 6.10;
P\0.05) than other patients, especially male patients in
the control group (meanAdj = 41.2, 95% CI: 37.8–44.6)
(Table 6).
1850 patients were invited to participate in the 
study between September 2004 and January 
2005
587 patients accepted the invitation to 
participate
1263 patients turned down invitation or did 
not respond at all: unwilling to participate in a 
study, not interested, unable to work with 
computer, insufficient grasp of the Dutch 
language, bad physical condition.
244 did not show up for questionnaire 
completion at the computer: were called in for 
consultation with physician before they were 
able to complete the questionnaire; forgotten 
and unknown reasons 
343 patients completed the questionnaires
327 patients were included in the study:
Male (n, %)  = 182 (56)
Female (n, %)  = 145 (44)
Age (Mean, range)   = 48 (20-81)
16 patients were excluded from the study as 
encountered language problems made valid 
administration doubtful  
162 patients were included in the data 
analyses:
Male (n, %)  = 96 (60) 
Female (n, %)  = 66 (40)
Age (Mean, range)   = 48 (20-75)
165 patients were excluded from the data 
analyses:
Male (n, %)  = 87
Female (n, %) = 78
Age (Mean, range) = 49 (20-81)
Reasons for exclusion:
- 19 patients had equal amount of 
consultations in both the control and 
experimental group
- 146 patients completed the questionnaires 
only once
Fig. 2 Patients in the study
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effect or interaction effects were found for the variables
feedback of HRQoL data and age, gender, and disease
severity on the SF-12 PCS.
Patients’ satisfaction with the consultation
The scores on patient satisfaction did not differ signiﬁ-
cantly between the experimental and control groups
(z =- 1.20, P = 0.23). Also, no interaction effects of age,
gender, and/or disease severity were found on this outcome
variable.
Effects of the experimental condition on the consultation
and on patient management
Physicians in the experimental group requested informa-
tion of their patients in 92% of consultations, and they
discussed it with their patients in 58% of consultations.
They indicated ﬁnding the HRQoL information useful in
45% of consultations, which is generally in accordance
with the percentage of patients in the experimental group
scoring below average on the MCS (39%) and PCS (42%).
They mostly found the HRQoL useless when a patient was
doing well. Physicians in the experimental group indicated
signiﬁcantly more often than physicians in the control
group that they spent more time than usual discussing
psychosocial issues (30.7% vs. 6.6% of consultations,
z =- 6.65; P\0.001). Treatment policy was altered
signiﬁcantly more often in the experimental group (11%
of consultations vs. 1% of consultations in the control
group; z =- 3.73, P\0.001). Most commonly, frequency
of consultations was increased (n = 5). Other alterations
Table 1 Differences in age, gender, diagnosis, and disease severity between patients in the study and nonrespondents
Patients in the
analyses (n = 162)
Patients excluded from
the analyses (n = 165)
P value Patients excluded from
the study (n = 260)
P value
Age, mean (range) 47.5 (20–75) 48.6 (20–81) 0.52 47.6 (18–80) 0.92
Gender, n (%)
Male 96 (59) 87 (53) 0.24 136 (52) 0.21
Female 66 (41) 78 (47) 124 (48)
Diagnosis, n (%)
Hepatitis B 22 (13) 25 (15) 0.04 49 (19) 0.00
Hepatitis C 23 (14) 24 (15) 56 (22)
Cholestatic liver disease 11 (7) 22 (13) 32 (12)
Pretransplantation 11 (7) 7 (4) 1 (0)
Posttransplantation 62 (38) 48 (29) 55 (21)
Autoimmune hepatitis 12 (8) 11 (7) 18 (7)
Other 21 (13) 28 (17) 49 (19)
Disease severity, n (%)
No cirrhosis 101 (62) 105 (64) 0.43 159 (61) 0.96
Compensated cirrhosis 42 (26) 45 (27) 69 (27)
Decompensated cirrhosis 19 (12) 15 (9) 32 (12)
Differences were assessed by means of v
2 tests (except for age: t test). Reference group for comparison of both P values is the group of patients in
the analyses
Table 2 Characteristics of patients included in the data analysis
Control
group
(n = 80)
Experimental
group
(n = 82)
P value
Gender, n (%)
Women 38 (48) 28 (34) 0.08
Men 42 (52) 54 (66)
Age, mean (range) 47.5 (21–74) 47.6 (20–74) 0.98
Diagnosis, n (%)
Hepatitis B 1 (1) 20 (25) 0.00
Hepatitis C 7 (9) 16 (19)
Cholestatic liver disease 4 (5) 6 (7)
Pretransplantation 5 (6) 3 (4)
Posttransplantation 43 (54) 23 (28)
Autoimmune hepatitis 6 (7) 6 (7)
Other 14 (18) 8(10)
Disease severity, n (%)
No cirrhosis 44 (55) 56 (68) 0.01
Compensated cirrhosis 16 (20) 22 (27)
Decompensated
cirrhosis
20 (25) 4 (5)
Differences were assessed by means of v
2 tests (except for age: t test)
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123concerned prescription of medication [3], increased atten-
tion for physical complaints [4], referral to psychosocial
care [1] or occupational health physician [1], and increased
attention to explanations/reassurance [2].
Physicians’ experiences with the availability of HRQoL
information in clinical practice
Experiences of physicians in the experimental group at
6 months and at the end of the study did not differ. All
physicians in the experimental condition found the HRQoL
information useful, except for one older physician who
claimed to know his patients very well. They indicated
being better able to understand some of their patients
through the extra information that was provided by the
questionnaires. These physicians did not perceive request-
ing the information as an extra effort on their part.
Furthermore, they did not think that using the information
lengthened their consultations. All physicians in the
experimental group indicated that they wanted to continue
using the HRQoL information in the future. Physicians in
the control group were similarly positive toward the pos-
sible availability of HRQoL information during their
consultations in the future, on the condition that it wouldnot
be time consuming. This speciﬁcally concerned patients
awaiting liver transplantation, patients with hepatitis C, and
nonnative speakers (mostly patients with hepatitis B).
Table 3 Questionnaire completion rate of patients in the control and experimental groups
Number of times questionnaires were completed Total (n)
2 3 4 56891 1
Control (n) 2 22 91 177121 8 0
Experimental (n) 4 51 8 952210 8 2
Table 4 Patients’ adjusted means and 95% conﬁdence intervals at T1 and T2-Ti
T1 P value T2-Ti P value
Control Experimental Control Experimental
Overall
SF-12 PCS 41.5 (39.0–43.9) 45.6 (42.0–49.3) 0.06 42.0 (39.6–44.4) 44.8 (41.4–48.3) 0.19
SF-12 MCS 43.4 (40.3–46.5) 46.0 (41.4–50.6) 0.35 43.8 (41.0–46.5) 44.8 (40.8–48.8) 0.69
LDSI 2.0 21.2 (19.0–23.4) 18.9 (15.7–22.2) 0.27 20.4 (18.6–22.2) 18.8 (16.1–21.4) 0.31
Male patients
SF-12 PCS 10.2 (37.1–43.3) 47.0 (42.9–51.2) 0.10 41.3 (38.2–44.2) 45.7 (41.7–49.7) 0.29
SF-12 MCS 41.6 (37.7–45.4) 45.6 (40.4–50.8) 0.49 41.2 (37.8–44.6) 46.7 (42.1–51.2) 0.02
LDSI 2.0 22.8 (20.0–25.5) 18.1 (14.4–21.8) 0.10 21.4 (19.2–23.6) 18.0 (15.0–21.0) 0.14
Female patients
SF-12 PCS 42.7 (39.2–46.3) 44.2 (39.8–48.7) 42.8 (39.4–46.2) 44.0 (39.7–48.2)
SF-12 MCS 45.2 (40.7–49.6) 46.4 (40.8–52.0) 46.3 (42.4–50.2) 42.9 (37.9–47.8)
LDSI 2.0 19.6 (16.4–22.8) 19.8 (15.8–23.8) 19.4 (16.9–22.0) 19.5 (16.3–22.7)
Older patients
SF-12 PCS 41.5 (38.4–44.6) 44.6 (40.7–48.6) 0.49 40.4 (37.4–43.3) 43.4 (39.9–47.5) 0.72
SF-12 MCS 41.5 (37.6–45.4) 46.3 (41.4–51.3) 0.26 41.2 (37.8–44.7) 45.9 (41.6–50.3) 0.03
LDSI 2.0 22.8 (20.0–25.5) 19.1 (15.6–22.7) 0.31 22.1 (19.9–24.3) 18.1 (15.3–21.0) 0.04
Younger patients
SF-12 PCS 41.4 (37.9–44.9) 46.7 (42.2–48.6) 43.6 (40.3–47.0) 45.9 (41.6–50.3)
SF-12 MCS 45.3 (40.9–49.7) 45.7 (40.0–51.3) 46.3 (42.5–50.2) 43.6 (38.7–48.6)
LDSI 2.0 19.6 (16.5–22.7) 18.7 (14.7–22.8) 18.8 (16.2–21.3) 19.4 (16.1–22.6)
The means at T1 and T2-Ti were obtained from the univariate analyses of variance with ﬁxed factors: age, gender, severity of the disease, study
group (control or experimental), and interactions between these variables. Differences in diagnoses between patients in both groups were
controlled for. The signiﬁcance level reﬂects the group for which the largest difference on the variable was found
SF-12 Short Form-12, PCS Physical Component Summary, MCS Mental Component Summary, LDSI 2.0 Liver Disease Symptom Index 2.0
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Computerized, real-time measurement of HRQoL at our
busy outpatient Department of Hepatology and presenta-
tion of the results to physicians before each consultation
did not show a main effect on patients’ overall HRQoL.
However, secondary analyses showed that the HRQoL
measurements positively affected disease-speciﬁc HRQoL
and generic mental HRQoL of older patients ([48 years of
age) with CLD and also generic mental HRQoL of male
CLD patients. The results of our study are among the ﬁrst
to show a beneﬁcial effect of presenting HRQoL data to
physicians in clinical practice. Most other studies have
failed to show evidence for the actual improvement in
HRQoL or psychosocial outcomes [9, 17–20]. Of the
studies that did ﬁnd a beneﬁcial effect, one showed a
decrease in disease-speciﬁc debilitating symptoms [13],
and another showed improved emotional functioning [10],
which is in line with ﬁndings of our study. It should be
noted that due to the cross-sectional data analyses, a causal
relationship between intervention and HRQoL could not be
demonstrated. Future studies should address this in further
detail.
Our study found no differences between patients in the
experimental and control groups with regard to satisfaction
with the consultation, which is in line with ﬁndings from
previous studies [9, 36, 37]. The lack of observed differ-
ences between the study groups may have been due to high
levels of satisfaction, resulting in a ceiling effect.
This study was among the ﬁrst to show a signiﬁcant
difference in patient management between experimental
and control groups, with physicians in the experimental
group mostly reporting a signiﬁcant increase in the fre-
quency of consultations. Our ﬁndings were statistically
signiﬁcant and in accordance with the ﬁndings of a sys-
tematic review [20] and subscribe to the increasingly
acknowledged importance of using HRQoL information for
the improvement of physician consultations [38]. However,
it should be noted that even though the differences in
patient management between control experimental groups
were statistically signiﬁcant, the absolute numbers were
small. Therefore, the results should be interpreted cau-
tiously, and further studies using more elaborate methods
of data collection—for instance, monitoring patients’
medical records or administering more detailed check-
lists—are recommended.
Physicians’ experiences with using HRQoL information
during the consultation were generally positive; requesting
the information was not considered an extra effort on their
part, and they found the information especially useful for
certain groups of patients, such as those awaiting liver
transplantation, those with hepatitis C, and nonnative
speakers. All physicians but one found the information
useful for at least some (45%) of their patients. Physicians
indicated ﬁnding the information least useful when patients
were doing well in terms of HRQoL or when they knew the
patient well. These generally positive experiences are in
accordance with ﬁndings from previous studies [9–14],
which assessed oncologists’ attitudes toward using HRQoL
information in clinical practice. The conﬁrmation of these
results in hepatologists suggests that HRQoL information
may also be well accepted by physicians treating patients
with other chronic conditions. Another result of our study
was that when HRQoL information was available, more
time was spent discussing psychosocial issues and more
treatments were altered. Interview and checklist data were
contradictory regarding the duration of consultations when
HRQoL information was available. In a previous study in
Table 5 Interaction effects between age, gender, disease severity,
and feedback on the outcome variable disease-speciﬁc HRQoL,
controlled for diagnosis
Source F value df P value R
2
Corrected model 2.11 10 0.03
Intercept 599.83 1 0.00
Diagnosis (propensity score) 1.80 1 0.18 0.08
Gender 0.04 1 0.85
Disease severity 3.39 2 0.04
Age 0.84 1 0.36
Feedback 1.05 1 0.31
Gender * Feedback 2.17 1 0.14 0.12
Severity * Feedback 0.15 2 0.86
Age * Feedback 4.18 1 0.04
Dependent variable: mean total score of the Liver Disease Symptom
Index 2.0 [disease-speciﬁc health-related quality of life (HRQoL)] for
the measurement moments T2...Ti
Table 6 Univariate analysis of variance with the variables age,
gender, disease severity, and feedback on the outcome variable
mental generic HRQoL, controlled for diagnosis
Source F value df P value R
2
Corrected model 1.65 10 0.10
Intercept 1337.05 1 0.00
Diagnosis (propensity score) 1.34 1 0.25 0.03
Gender 0.14 1 0.71
Disease severity 0.40 2 0.67
Age 0.65 1 0.42
Feedback 0.16 1 0.69
Gender * Feedback 6.10 1 0.02 0.10
Severity * Feedback 0.13 2 0.88
Age * Feedback 4.62 1 0.03
Dependent variable: mean total score of Short Form-12 Mental
Component Summary (SF-12 MCS) [generic mental-health-related
quality of life (HRQoL)] for the measurement moments T2...Ti
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123which the duration of consultations was timed, no increase
in consultation time was found [14]. Future studies should
shed more light on whether the availability of HRQoL
information increases the length of consultations in
hepatology.
The strength of our study lies in the analyses performed,
where beneﬁts for speciﬁc groups of liver patients were
explored by entering interactions between gender, age,
disease severity, and feedback of HRQoL data, rather than
solely investigating main effects between the intervention
and control groups. Also, this study included patients with
CLD rather than patients with cancer or patients from
general practice, making it especially relevant to a more
general population of patients with a chronic illness.
We are aware of several limitations of this study. First,
physicians rather than patients were randomly assigned to
either the intervention or control group. Randomization is a
complicated issue in these kinds of implementation studies,
and both methods are subject to limitations. An important
advantage of the randomization of physicians is that the
control group was not biased toward mentioning HRQoL
topics more often than usual. Future studies using the same
design but including more physicians are needed to further
explore possible main effects of HRQoL measurement on
patients’ overall HRQoL. A second limitation was the high
number of nonparticipants. Part of the explanation may lie
in the fact that patients were responsible for contacting
their physician if they were interested in participating in
the study. In addition, the number of non-Dutch-speaking
patients visiting the department is relatively large (hepatitis
B, for example, is most common among people from North
Africa). These patients were also invited to participate but
were less likely to respond. The relatively large number of
patients who completed the questionnaires only once may
be explained by the small window of opportunity to com-
plete the questionnaires before each consultation. In
addition, for such implementation endeavors, cooperation
of all staff members is essential, and future research should
explore this further. A last limitation of this study was that
the checklists used to assess consultation content were not
very detailed. This was done on purpose, as longer
inventories would have compromised physician participa-
tion. However, considering the positive outcomes of this
study, it is advisable that future studies consider ways to
obtain a more detailed view of how the HRQoL informa-
tion affects consultation content, for example, by recording
consultations.
In conclusion, although a main effect of the intervention
was not found, this study showed a beneﬁcial effect of
implementation of HRQoL measurement in clinical prac-
tice on the HRQoL of older and male patients with CLD
and on patient management. Nevertheless, the study had
several shortcomings, and further studies are needed to
substantiate these ﬁndings. Physicians’ experiences with
the availability of HRQoL information were positive,
especially for patients awaiting liver transplantation,
patients with hepatitis C, and nonnative speakers. They
expressed an interest in continued use of HRQoL infor-
mation. These results advocate the continued use of
measuring HRQoL in a clinical practice of hepatology.
Including older patients and male patients, who have been
shown to beneﬁt most from such a procedure, should be
aimed for.
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